Sacituzumab tirumotecan for advanced anal/rectal cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug, sacituzumab tirumotecan, in people with squamous cell carcinoma of the anus or rectum that has spread or cannot be removed. It aims to see if the drug can shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have squamous cell carcinoma of the anus or rectum that has spread to other parts of the body or cannot be removed with surgery.
- You must have had at least one but no more than three previous cancer treatments (chemotherapy, immunotherapy, or both) for advanced disease.
- You should be 18 years or older and in good enough health to carry out daily activities (ECOG score 0 or 1).
- You must provide a tumor tissue sample from a previous biopsy for testing.
- You must have adequate kidney, liver, and bone marrow function based on blood tests.
- You cannot have had certain prior treatments, such as irinotecan, topotecan, or drugs that target TROP2.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called sacituzumab tirumotecan for a rare and aggressive type of kidney cancer called renal medullary carcinoma (RMC) or a related variant. The drug is designed to target and deliver treatment directly to cancer cells. The study aims to see if it can shrink tumors or slow the disease in people who have already tried other treatments.
This trial tests a new targeted drug, sacituzumab tirumotecan, for people with advanced small bowel adenocarcinoma that has not responded to or cannot tolerate platinum-based chemotherapy. The drug targets a protein called TROP2 on cancer cells to deliver treatment directly to them.
This trial tests a new drug, sacituzumab tirumotecan, in people with advanced thymic carcinoma that has spread or cannot be removed with surgery. It is for those whose cancer has gotten worse after at least one round of platinum-based chemotherapy.
This trial tests a new drug called sacituzumab tirumotecan for pancreatic cancer that has progressed despite prior treatment. The drug is designed to target cancer cells and deliver chemotherapy directly to them, potentially working better with fewer side effects.
This trial tests a new targeted drug (sacituzumab tirumotecan) for people with advanced thymic cancer that has gotten worse after at least one prior treatment. The goal is to see if the drug can shrink tumors and improve outcomes.
This study tests a new drug called sacituzumab tirumotecan for people with thymic carcinoma that has spread or come back after platinum-based chemotherapy. The drug targets a protein on cancer cells to deliver chemotherapy directly to them, which may help shrink tumors or slow their growth.
Hear when a new Phase 2 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.